Publications by authors named "Yen Ngai"
Int J Gynecol Cancer
August 2024
Article Synopsis
- An immunotherapy targeting the 5T4 tumor antigen was tested in a clinical trial to determine if it could delay chemotherapy in patients with asymptomatic relapsed ovarian cancer.
- The phase II study, TRIOC, was randomized, placebo-controlled, and aimed to evaluate both the effectiveness and safety of the MVA-5T4 treatment among patients meeting specific eligibility criteria.
- Results showed that the median progression-free survival was similar for both the MVA-5T4 group (59 patients) and placebo group (35 patients), with an 80% progression rate for MVA-5T4 compared to 85.7% for placebo, indicating no significant advantage for the immunotherapy.
